ST. LOUIS, MO – PierianDx, the forerunner in clinical genomic analysis, interpretation and reporting, announced it has added several new customers in the first quarter of 2016. The new customers include leading health systems, academic medical centers, children’s hospitals, and commercial labs in the U.S. and around the world.
PierianDx provides the essential workspace for clinical genomicists through its platform, Clinical Genomicist Workspace (CGW), a complete suite of modules that delivers an integrated, data-driven ecosystem for analytics, variant identification and classification, interpretation, and reporting.
“We are honored and excited to be partnering with some of the most innovative leaders in healthcare,” said Ted Briscoe, CEO of PierianDx. “This further validates the CGW platform and continues to expand the value of our knowledgebase and sharing network.”
In the last few months, the following customers selected PierianDx to accelerate their clinical testing initiatives:
- Seattle Children’s (Seattle, WA)
- UAB Hospital
- St. Luke’s Hospital (St. Louis, MO)
- University of Miami (Miami, FL)
- Wake Forest Baptist Health (Winston-Salem, NC)
- Sonic Healthcare (Austin, TX)
- Advanced Clinical Labs (Brooklyn, NY)
- Alpha Genomix Laboratories (Atlanta, GA)
- Prashanti Cancer Care Mission (Pune, India)
- Q2 Solutions (Raleigh, NC)
CGW is driven by the PierianDx Collaborative Knowledgebase™, a comprehensive database comprised of millions of biomedical findings that are constantly updated. The knowledgebase leverages multiple databases to analyze and classify each Media Contact: Brad Herrick (314) 238-4476 firstname.lastname@example.org detected variant, allowing CGW to deliver the most clinically actionable results available. Each partner added to the PierianDx community expands the intelligence of the knowledgebase through facilitated sharing among network members while protecting patient privacy and intellectual property.
In addition to the Clinical Genomicist Workspace, PierianDx enables customer laboratory initiatives with professional services and the NGS Gateway Program, a turnkey, outsourced service that provides customers with an on-ramp to in-house NGS testing.
PierianDx enables health systems, academic medical centers, cancer centers, and commercial labs to deliver patient-specific diagnosis and treatments based on an individual’s DNA. Developed by Washington University Medical Center in 2011, and regularly enhanced with new patient, clinical and research data, PierianDx’s proprietary Clinical Genomicist Workspace provides clinical labs the essential tools to accelerate their Personalized Medicine programs: streamlined and accurate analysis, insightful interpretation, and precise reporting.
For more information, please visit www.pieriandx.com or @PierianDx on Twitter. Media Contact: Brad Herrick email@example.com 314-238-4476